Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Finished Goods: 2014-2025

Historic Finished Goods for Ocular Therapeutix (OCUL) over the last 6 years, with Sep 2025 value amounting to $1.9 million.

  • Ocular Therapeutix's Finished Goods rose 134.86% to $1.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 134.86%. This contributed to the annual value of $1.3 million for FY2024, which is 34.91% up from last year.
  • Per Ocular Therapeutix's latest filing, its Finished Goods stood at $1.9 million for Q3 2025, which was up 75.28% from $1.1 million recorded in Q2 2025.
  • Over the past 5 years, Ocular Therapeutix's Finished Goods peaked at $1.9 million during Q3 2025, and registered a low of $257,000 during Q4 2021.
  • Its 3-year average for Finished Goods is $1.2 million, with a median of $1.2 million in 2024.
  • Per our database at Business Quant, Ocular Therapeutix's Finished Goods slumped by 61.26% in 2021 and then spiked by 198.05% in 2022.
  • Ocular Therapeutix's Finished Goods (Quarterly) stood at $257,000 in 2021, then soared by 198.05% to $766,000 in 2022, then rose by 29.37% to $991,000 in 2023, then soared by 34.91% to $1.3 million in 2024, then surged by 134.86% to $1.9 million in 2025.
  • Its Finished Goods was $1.9 million in Q3 2025, compared to $1.1 million in Q2 2025 and $1.3 million in Q1 2025.